Kairos Pharma Wins Award for Drug Resistance Breakthroughs

Kairos Pharma (NYSE American: KAPA) has been honored as the USA leader in drug resistance development in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards. This recognition underscores the company's pioneering work in developing cancer therapeutics that combat treatment resistance, a major hurdle in oncology. By focusing on innovative approaches to target drug resistance, Kairos Pharma aims to extend the efficacy of existing cancer therapies, offering new hope for patients whose treatments have become less effective over time.

Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 is designed to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.

The award and the progress of ENV-105 highlight Kairos Pharma's potential to make a substantial impact in cancer treatment. The company's innovative approach could provide new options for patients with resistant cancers, potentially improving outcomes and quality of life. For investors, the recognition and clinical progress signal a promising opportunity in the biotech sector. More information about Kairos Pharma and its developments can be found at the company’s newsroom at https://ibn.fm/KAPA. Additionally, this announcement was disseminated by BioMedWire, a part of the Dynamic Brand Portfolio @ IBN, highlighting the importance of staying informed about groundbreaking developments in the life sciences sector.